Literature DB >> 7778538

Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group.

H B Rubins1, S J Robins, D Collins, A Iranmanesh, T J Wilt, D Mann, M Mayo-Smith, F H Faas, M B Elam, G H Rutan.   

Abstract

In the present study we measured fasting lipid profiles in over 8,500 community-living men with coronary artery disease (CAD) to determine the distribution of lipid abnormalities in this population: 81% were white and 16% black; mean age 62.9 +/- 8 years; mean total cholesterol 214 +/- 41 mg/dl; low-density lipoprotein (LDL) cholesterol 140 +/- 37 mg/dl; high-density lipoprotein (HDL) cholesterol 39 +/- 11 mg/dl; and triglycerides 190 +/- 142 mg/dl. After adjusting for age, the only significant difference between blacks and whites was a higher HDL cholesterol in blacks (45 vs 38 mg/dl, p < 0.003). With use of cut points established by the National Cholesterol Education Program, 87% of subjects had high LDL cholesterol (> or = 100 mg/dl), 38% had low HDL cholesterol (< 35 mg/dl), and 33% had high triglycerides (> 200 mg/dl). We estimated that 42% of men with CAD would be definite candidates for cholesterol-lowering medication according to the National Cholesterol Education Program guidelines and that 41% of those in whom cholesterol-lowering medication would not be definitely indicated had low levels of HDL cholesterol. We conclude that (1) black men with CAD have substantially higher HDL cholesterol than white men, (2) almost 90% of male patients with CAD are candidates for dietary intervention and > 40% may need medications to lower LDL cholesterol, and (3) 40% of patients without a definite indication for cholesterol-lowering medications have low levels of HDL cholesterol.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7778538     DOI: 10.1016/s0002-9149(99)80761-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  26 in total

Review 1.  Novel serologic markers of cardiovascular risk.

Authors:  Guilherme H M Oliveira
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

2.  A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.

Authors:  Donald B Hunninghake; Mark E McGovern; Michael Koren; Ronald Brazg; David Murdock; Stuart Weiss; Thomas Pearson
Journal:  Clin Cardiol       Date:  2003-03       Impact factor: 2.882

Review 3.  HDL hypothesis: where do we stand now?

Authors:  Sayed M Tariq; Mandeep S Sidhu; Peter P Toth; William E Boden
Journal:  Curr Atheroscler Rep       Date:  2014-04       Impact factor: 5.113

4.  Risk-sensitive therapeutic strategies for coronary artery disease: toward testing-driven therapy in stable angina patients with low-to-intermediate risk cardiac imaging results.

Authors:  D D Miller; B J Gersh
Journal:  J Nucl Cardiol       Date:  1997 Sep-Oct       Impact factor: 5.952

5.  High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: the InChianti study.

Authors:  Giovanni Zuliani; Stefano Volpato; Alessando Blè; Stefania Bandinelli; Anna Maria Corsi; Fulvio Lauretani; Giuseppe Paolisso; Renato Fellin; Luigi Ferrucci
Journal:  Atherosclerosis       Date:  2006-06-19       Impact factor: 5.162

Review 6.  New developments in the prevention of atherosclerosis in patients with low high-density lipoprotein cholesterol.

Authors:  M E Brousseau; E J Schaefer
Journal:  Curr Atheroscler Rep       Date:  2001-09       Impact factor: 5.113

Review 7.  Niacin, lipids, and heart disease.

Authors:  Shaista Malik; Moti L Kashyap
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

Review 8.  Plasma lipoprotein concentrations in ethnic populations.

Authors:  Karol E Watson
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

Review 9.  Role of fibric acid derivatives in the management of risk factors for coronary heart disease.

Authors:  Jean-Pierre Després; Isabelle Lemieux; Sander J Robins
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  Is a statin as part of a polypill the answer?

Authors:  Jennifer G Robinson
Journal:  Curr Atheroscler Rep       Date:  2009-01       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.